← Back to Search

IDH Inhibitor

AG-881 for Brain Tumor

Phase 1
Waitlist Available
Research Sponsored by Agios Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up up to 26 weeks, on average
Awards & highlights

Study Summary

This trial is testing a new drug for patients with brain tumors that have a specific genetic mutation.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 26 weeks, on average
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 26 weeks, on average for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose and/or the recommended Phase II dose of AG881 in patients with advance solid tumors, including gliomas
Safety/Tolerability; incidence of adverse events
Secondary outcome measures
Clinical Activity according to RECIST v 1.1 (2009) for patients with solid tumors, by RANO (2010) criteria for patients with glioma
Pharmacodynamic levels of 2-HG
Pharmacodynamic levels of AG-881
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: AG881Experimental Treatment1 Intervention
AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Find a Location

Who is running the clinical trial?

Agios Pharmaceuticals, Inc.Lead Sponsor
52 Previous Clinical Trials
4,111 Total Patients Enrolled
Institut de Recherches Internationales ServierLead Sponsor
86 Previous Clinical Trials
67,041 Total Patients Enrolled

Media Library

AG-881 (IDH Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02481154 — Phase 1
Brain Tumor Research Study Groups: AG881
Brain Tumor Clinical Trial 2023: AG-881 Highlights & Side Effects. Trial Name: NCT02481154 — Phase 1
AG-881 (IDH Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02481154 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many locales are overseeing this trial?

"Potential participants in this research project can find enrolling sites at various locations, such as UT Southwestern Medical Center Miami, UCLA Oncology Centre New york and Memorial Sloan Kettering Cancer Center Los Angeles. Additionally, there are another 18 hospitals that have been approved to recruit patients for the study."

Answered by AI

Does this trial presently have open enrollment?

"According to clinicaltrials.gov, this trial is no longer enrolling participants and has not been actively recruiting since May 16th 2022. However, there are 355 other studies that currently require volunteers."

Answered by AI

What potential risks does AG881 pose for individuals who take it?

"The safety of AG881 was rated 1 on our team's scale, due to limited clinical data supporting both its efficacy and safety."

Answered by AI
~10 spots leftby Apr 2025